Compare BHR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | ANTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 172.9M |
| IPO Year | N/A | 2022 |
| Metric | BHR | ANTX |
|---|---|---|
| Price | $2.29 | $4.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 662.9K | 196.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $1.00 |
| 52 Week High | $3.19 | $6.91 |
| Indicator | BHR | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 56.37 |
| Support Level | $2.19 | $3.91 |
| Resistance Level | $2.61 | $5.15 |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 97.14 | 66.67 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.